Literature DB >> 15636699

Clinical responses to sildenafil in Waldenstrom's macroglobulinemia.

Steven P Treon1, Olivier Tournilhac, Andrew R Branagan, Zachary Hunter, Lian Xu, Evdoxia Hatjiharissi, Daniel D Santos.   

Abstract

Waldenstrom's macroglobulinemia (WM) is an incurable B-cell malignancy. Interestingly, an unusual response activity was observed in 5 patients with WM that appeared related to their use of sildenafil, a phosphodiesterase inhibitor used to treat erectile dysfunction. One patient demonstrated a complete remission, and 4 other patients demonstrated less dramatic, but also unexpected, responses associated with sildenafil. In view of these findings, WM tumor cells were culture-sorted with sildenafil at pharmacologically achievable levels and apoptosis was demonstrated in tumor cells from all 5 patients. These studies suggest that sildenafil may be an active agent in the treatment of WM.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15636699     DOI: 10.3816/clm.2004.n.029

Source DB:  PubMed          Journal:  Clin Lymphoma        ISSN: 1526-9655


  9 in total

Review 1.  Update on therapeutic options in Waldenström macroglobulinemia.

Authors:  Xavier Leleu; Julie Gay; Aldo M Roccaro; Anne-Sophie Moreau; Stephanie Poulain; Remy Dulery; Berenice Bro Des Champs; Daniela Robu; Irene M Ghobrial
Journal:  Eur J Haematol       Date:  2009-01       Impact factor: 2.997

2.  Aggregating case reports: a way for the future of evidence-based health care?

Authors:  Debra Jackson; John Daly; Deborah C Saltman
Journal:  Clin Case Rep       Date:  2014-04

Review 3.  Sildenafil Can Affect Innate and Adaptive Immune System in Both Experimental Animals and Patients.

Authors:  Monika Kniotek; Agnieszka Boguska
Journal:  J Immunol Res       Date:  2017-02-20       Impact factor: 4.818

Review 4.  New developments in the management of Waldenström macroglobulinemia.

Authors:  Jithma P Abeykoon; Uday Yanamandra; Prashant Kapoor
Journal:  Cancer Manag Res       Date:  2017-03-10       Impact factor: 3.989

5.  The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial.

Authors:  Donald T Weed; Serena Zilio; Isildinha M Reis; Zoukaa Sargi; Marianne Abouyared; Carmen R Gomez-Fernandez; Francisco J Civantos; Carla P Rodriguez; Paolo Serafini
Journal:  Front Immunol       Date:  2019-05-31       Impact factor: 7.561

Review 6.  New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil.

Authors:  Marian Cruz-Burgos; Alberto Losada-Garcia; Carlos D Cruz-Hernández; Sergio A Cortés-Ramírez; Ignacio Camacho-Arroyo; Vanessa Gonzalez-Covarrubias; Miguel Morales-Pacheco; Samantha I Trujillo-Bornios; Mauricio Rodríguez-Dorantes
Journal:  Front Oncol       Date:  2021-02-26       Impact factor: 6.244

7.  Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias.

Authors:  Aldo M Roccaro; Irene M Ghobrial; Simona Blotta; Steven P Treon; Michele Malagola; Kenneth C Anderson; Paul G Richardson; Domenico Russo
Journal:  Biologics       Date:  2008-09

8.  Case reports and the fight against cancer.

Authors:  Elie G Dib; Michael R Kidd; Deborah C Saltman
Journal:  J Med Case Rep       Date:  2008-02-06

9.  Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents.

Authors:  Pan Pantziarka; Vidula Sukhatme; Sergio Crispino; Gauthier Bouche; Lydie Meheus; Vikas P Sukhatme
Journal:  Ecancermedicalscience       Date:  2018-04-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.